Compile Data Set for Download or QSAR
Report error Found 31 Enz. Inhib. hit(s) with all data for entry = 8114
Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233390(US9346829, 29)
Affinity DataIC50: 0.462nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233364(US9346829, 6 | US9346829, 2)
Affinity DataIC50: 0.510nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233373(US9346829, 11)
Affinity DataIC50: 0.600nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233367(US9346829, 5)
Affinity DataIC50: 0.620nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233384(US9346829, 22)
Affinity DataIC50: 0.650nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233372(US9346829, 10)
Affinity DataIC50: 0.650nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233377(US9346829, 15)
Affinity DataIC50: 0.662nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233371(US9346829, 9)
Affinity DataIC50: 0.680nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233366(US9346829, 4)
Affinity DataIC50: 0.690nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233375(US9346829, 13)
Affinity DataIC50: 0.720nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233391(US9346829, 30)
Affinity DataIC50: 0.745nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233379(US9346829, 17)
Affinity DataIC50: 0.75nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233365(US9346829, 8 | US9346829, 3)
Affinity DataIC50: 0.810nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233374(US9346829, 12)
Affinity DataIC50: 0.882nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233363(US9346829, 1)
Affinity DataIC50: 0.950nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233365(US9346829, 8 | US9346829, 3)
Affinity DataIC50: 0.960nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233385(US9346829, 23)
Affinity DataIC50: 1.01nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233364(US9346829, 6 | US9346829, 2)
Affinity DataIC50: 1.10nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233383(US9346829, 21)
Affinity DataIC50: 1.10nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233387(US9346829, 26)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233376(US9346829, 14)
Affinity DataIC50: 1.34nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233393(US9346829, 32)
Affinity DataIC50: 1.36nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233386(US9346829, 25)
Affinity DataIC50: 1.39nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233388(US9346829, 27)
Affinity DataIC50: 1.44nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233382(US9346829, 20)
Affinity DataIC50: 1.5nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233380(US9346829, 18)
Affinity DataIC50: 2.01nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233389(US9346829, 28)
Affinity DataIC50: 2.04nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233378(US9346829, 16)
Affinity DataIC50: 2.5nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233369(US9346829, 7)
Affinity DataIC50: 2.86nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233381(US9346829, 19)
Affinity DataIC50: 3.68nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM233392(US9346829, 31)
Affinity DataIC50: 1.00E+3nMT: 2°CAssay Description:The 5-HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2017
Entry Details
Go to US Patent